Skip to main content

Table 3 Hazard ratios and corresponding 95% confidence intervals for the association between circulating TRAIL concentration at blood collection and survival outcomes, stratified by ERPR status

From: Postdiagnosis circulating osteoprotegerin and TRAIL concentrations and survival and recurrence after a breast cancer diagnosis: results from the MARIE patient cohort

  

TRAIL, all cases

ER-PR-

ER+ PR− or ER-PR + 

ER + PR + 

  

n/events

HRa

(95% CI)

p

n/events

HRb

(95% CI)

p

n/events

HRb

(95% CI)

p

n/events

HRb

(95% CI)

p

Phetc

All-cause mortality

Quartiles

1

614/132

 

 ref.

 

66/21

 

 ref.

 

99/19

 

 ref.

 

387/77

 

 ref.

  
 

2

614/111

0.80

(0.62–1.03)

 

78/22

0.79

(0.43–1.46)

 

93/18

0.94

(0.49–1.80)

 

385/61

0.79

(0.57–1.11)

 

0.71

 

3

615/124

0.93

(0.73–1.19)

 

81/24

0.94

(0.51–1.73)

 

83/20

1.29

(0.68–2.45)

 

393/74

0.91

(0.66–1.26)

  
 

4

614/118

0.86

(0.67–1.11)

 

84/20

0.71

(0.38–1.32)

 

92/17

1.00

(0.51–1.96)

 

371/69

0.89

(0.64–1.23)

  

Continuousd

2457/485

0.98

(0.87–1.11)

0.80

309/87

0.98

(0.73–1.31)

0.88

367/74

1.09

(0.81–1.46)

0.74

1536/281

0.96

(0.81–1.13)

0.62

0.67

Breast cancer-specific mortality

Quartiles

1

614/66

 

 ref.

 

66/11

 

 ref.

 

99/14

 

 ref.

 

387/34

 

 ref.

  
 

2

614/60

0.90

(0.64–1.29)

 

78/16

1.11

(0.51–2.42)

 

93/12

0.78

(0.36–1.72)

 

385/26

0.86

(0.51–1.45)

 

0.48

 

3

615/83

1.35

(0.97–1.87)

 

81/18

1.47

(0.67–3.24)

 

83/14

1.15

(0.54–2.44)

 

393/46

1.41

(0.90–2.20)

  
 

4

614/68

1.07

(0.76–1.50)

 

84/11

0.80

(0.34–1.87)

 

92/10

0.84

(0.36–1.95)

 

371/37

1.16

(0.72–1.86)

  

Continuousd

2457/277

1.10

(0.93–1.30)

0.26

309/56

1.06

(0.73–1.54)

0.76

367/50

0.98

(0.68–1.43)

0.96

1536/143

1.09

(0.86–1.38)

0.49

0.81

Recurrence-free survivale

Quartiles

1

546/133

 

 ref.

 

61/21

 

 ref.

 

92/22

 

 ref.

 

365/85

 

 ref.

  
 

2

566/118

0.81

(0.63–1.04)

 

71/23

0.94

(0.52–1.72)

 

92/20

0.78

(0.42–1.46)

 

369/70

0.79

(0.57–1.08)

 

0.80

 

3

570/136

0.98

(0.77–1.24)

 

77/25

0.97

(0.54–1.76)

 

80/21

1.04

(0.56–1.90)

 

371/89

1.04

(0.77–1.41)

  
 

4

559/121

0.89

(0.69–1.14)

 

79/24

0.97

(0.54–1.76)

 

83/15

0.79

(0.40–1.53)

 

349/79

0.93

(0.68–1.27)

  

Continuousd

2241/508

1.00

(0.88–1.13)

0.96

288/93

1.09

(0.82–1.46)

0.56

347/78

0.96

(0.72–1.28)

0.71

1454/323

1.01

(0.87–1.18)

0.88

0.88

  1. ERPR status was not available for 91 women who had neoadjuvant chemotherapy and 154 who were diagnosed tumor in situ or stage 0. ERPR-discordant includes ER+PR-, ER-PR+, ER+ or PR+ and data on other receptor unknown, or women treated with tamoxifen or aromatase inhibitor
  2. aAdjusted for age, nodal status, tumor size, and grade/strata for center, ERPR status
  3. bAdjusted for age, nodal status, tumor size, and grade/strata for center
  4. cHeterogeneity of estimates across ERPR status
  5. dLog-2-transformed
  6. ePatients without information on recurrence or with a tumor stages 3b, and 3c were excluded
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us